QN-247 / Qualigen Therap - LARVOL DELTA

Qualigen Therapeutics, Inc. Reports Financial Results and Corporate Update for Quarter Ending June 30, 2023 (GlobeNewswire) - "The $0.1 million increase in therapeutics research and development costs was primarily due to a $0.5 million increase in QN-302 pre-clinical research and development costs, offset by a decrease of pre-clinical research and development costs of $0.4 million for QN-247."

Commercial • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer

Qualigen Therapeutics, Inc. Reports Financial Results and Corporate Update for Quarter Ending March 31, 2023 (GlobeNewswire) - "Research and development costs increased from $1.9 million for the three months ended March 31, 2022 to $2.1 million for the three months ended March 31, 2023. Of the $2.1 million of research and development costs for the three months ended March 31, 2023, $1.3 million (60%) was attributable to therapeutics and $0.8 million (40%) was attributable to diagnostics....The decrease in therapeutics research and development costs was primarily due to a decrease of pre-clinical research and development costs of $0.6 million in QN-247 expenses, a decrease of $0.2 million in stock-based compensation expenses, a decrease in pan-RAS expenses of $0.1 million, offset by an increase in QN-302 pre-clinical research and development costs of $0.5 million."

Commercial • Gastrointestinal Cancer • Oncology • Pancreatic Cancer • Solid Tumor

Nano-immunotherapy: efficacy of nanoconjugate QN-247 in a triple negative breast cancer (TNBC) mouse model (AACR 2023) - "This study demonstrates that QN-247 exerts a powerful anti-tumor effect. Additional preclinical mouse xenograft tumor models will be treated with QN-247 to study its effect on other cancers."

IO biomarker • Preclinical • Breast Cancer • HER2 Breast Cancer • Hormone Receptor Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • ER • HER-2 • NCL • PGR

Qualigen Therapeutics Presents Data On QN-247 in Triple Negative Breast Cancer at the American Association for Cancer Research (AACR) Annual Meeting in Orlando, FL (GlobeNewswire) - "Qualigen Therapeutics, Inc...announces data from the Company’s poster presented at the American Association for Cancer Research (AACR) Annual Meeting 2023 held April 14-19 in Orlando, FL. The Company presented in vivo efficacy data regarding its QN-247 program, for which it is actively seeking partners....In addition, QN-247 is effective in vivo against a xenograft mouse TNBC model showing highly significant reductions in tumor volumes with no evidence of toxicity."

Preclinical • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer

Qualigen Therapeutics to Present Five Posters at the American Association for Cancer Research Annual Meeting 2023 (GlobeNewswire) - "Qualigen Therapeutics...announces the Company will be presenting five posters at the American Association for Cancer Research (AACR) Annual Meeting 2023....The Company will be presenting four posters regarding its lead program, QN-302, and one poster regarding an in-vivo study of program QN-247 in Triple Negative Breast Cancer (TNBC)."

Preclinical • Breast Cancer • Gastrointestinal Cancer • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor • Triple Negative Breast Cancer

Qualigen Therapeutics Reports Positive QN-247 Readout in Triple Negative Breast Cancer in Vivo Model (GlobeNewswire) - "Qualigen Therapeutics...announces it has completed its in vivo efficacy analysis of QN-247 in solid tumors. Data demonstrates robust efficacy and no safety signals in a triple negative breast cancer (TNBC) model. Committed to an in vivo data readout in the third quarter of 2022, the Company has been conducting in vivo testing on multiple potential indications. QN-247 demonstrated a robust efficacy signal and showed no adverse events or toxicities at the tested therapeutic dose in an animal model for triple negative breast cancer (TNBC), a rare, highly aggressive and difficult to treat form of breast cancer."

Preclinical • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer

Qualigen Therapeutics (BIO 2022) - "Our therapeutics pipeline includes cancer drug compounds such as QN-302, QN-247 (formerly referred to as AS1411-GNP or ALAN), and RAS-F, as well as STARS, a DNA/RNA-based treatment device. By combining our demonstrated ability to develop and commercialize innovative medical products with the advanced capabilities of leading cancer research centers, we are committed to providing exciting new therapeutic technologies to physicians and patients."

Oncology • Pediatrics

Qualigen Therapeutics, Inc. Provides Corporate Update and Reports First Quarter 2022 Financial Results (GlobeNewswire) - "Research and development costs decreased from $3.5 million for the three months ended March 31, 2021 to $1.9 million for the three months ended March 31, 2022. The reduction in expenses was primarily due to a $2.6 million decrease in pre-clinical research costs related to the potential application of QN-165 for the treatment of COVID-19 (which has since been deprioritized), offset by an increase of $0.4 million in pre-clinical research costs for QN-302, which we acquired in January 2022, an increase of $0.4 million in pre-clinical research costs for QN-247, an increase of $0.1 million in pre-clinical research costs for our RAS program..."

Commercial • Acute Myelogenous Leukemia • CNS Tumor • Gastrointestinal Cancer • Genito-urinary Cancer • Glioblastoma • Hematological Malignancies • Leukemia • Lung Cancer • Neuroblastoma • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Prostate Cancer • Solid Tumor • Urothelial Cancer

Qualigen Therapeutics Secures Option to Negotiate License for G-Quadruplex Anti-Cancer Technology from UCL (GlobeNewswire) - "Qualigen Therapeutics, Inc...announced...it has entered into a Material Evaluation and Option Agreement with the University College London (UCL) to advance development of and potentially expand toward future commercial uses of Qualigen's leading anticancer drug candidate AS1411-GNP, also known as ALAN...In collaboration with the University of Louisville, Qualigen will evaluate the use of ALAN with G-quadruplex binders (GQBs) developed by Professor Stephen Neidle and colleagues from UCL....The Company is aiming to commence Phase 1 human trials in 2021 for acute myeloid leukemia, its lead indication."

Licensing / partnership • New P1 trial • Acute Myelogenous Leukemia • Hematological Malignancies • Oncology

Qualigen Therapeutics Announces Issuance of U.S. Patent for Expanded Applications of ALAN Anticancer Platform Technology (PRNewswire) - "Qualigen Therapeutics, Inc...announced that the United States Patent and Trademark Office has issued a patent entitled 'Anti-Nucleolin Agent-Conjugated Nanoparticles as Radio-Sensitizers and/or MRI Contrast Agents' regarding the Company's ALAN (Aptamer-Linked Anti-Nucleolin) technology. This patent issued to the University of Louisville (UofL) protects the ALAN technology for use with cancer radiation therapy and for imaging tumors utilizing magnetic resonance imaging (MRI)...The Company plans to commence Phase 1 human trials with ALAN in 2021 in patients with acute myeloid leukemia..."

New P1 trial • Patent • Acute Myelogenous Leukemia • Hematological Malignancies • Oncology

Qualigen Therapeutics Expands Research Agreement with University of Louisville for ALAN Cancer Drug Candidate (PRNewswire) - "Qualigen Therapeutics, Inc...announces it has entered into an amended Sponsored Research Agreement with the University of Louisville (UofL) to advance development of Qualigen's anticancer drug candidate AS1411-GNP, also known as ALAN (Aptamer-Linked Anti-Nucleolin)...The Company is aiming to commence Phase 1 human trials in 2021 for AML, its lead indication. Qualigen has an exclusive worldwide license agreement from the UofL for ALAN."

Licensing / partnership • Acute Myelogenous Leukemia • Hematological Malignancies • Oncology